Microvolt T-Wave Alternans Testing To Be Covered by CIGNA HealthCare
6/28/2006 5:57:01 PM
BEDFORD, Mass., Jun 28, 2006 (BUSINESS WIRE) -- Cambridge Heart, Inc. ( CAMH ) today announced that CIGNA HealthCare has revised its Coverage Position on Microvolt T Wave Alternans testing, agreeing to make it a covered benefit for its beneficiaries. The Coverage Position now states:
"CIGNA HealthCare covers microvolt T-wave alternans (MTWA) testing as a method to identify risk of ventricular arrhythmias and sudden cardiac death for patients who meet criteria for implantable cardioverter defibrillator placement."
CIGNA HealthCare is one of the nations leading providers of healthcare benefits covering over 12 million people across the country.
"We are very pleased that after reviewing all of the published literature on Cambridge Heart's system, including last month's publication in JACC by Dr. Theodore Chow, CIGNA has recognized the benefit that MTWA can provide to their beneficiaries," said David Chazanovitz, President and CEO of Cambridge Heart, Inc. "The utilization of our diagnostic test in patients eligible for implantable defibrillator therapy is becoming more and more important as physicians work to provide the most appropriate individualized care for their patients."
